The intracellular parent of the cysteinyl leukotrienes (cysLTs), leukotriene (LT) C 4 , is formed by conjugation of LTA 4 and reduced glutathione by LTC 4 synthase in mast cells, eosinophils, basophils, and macrophages. After extracellular export, LTC 4 is converted to LTD 4 and LTE 4 through sequential enzymatic removal of glutamic acid and then glycine. Only LTE 4 is sufficiently stable to be prominent in biologic fluids, such as urine or bronchoalveolar lavage fluid, of asthmatic individuals and at sites of inflammation in animal models. LTE 4 has received little attention because it binds poorly to the classical type 1 and 2 cysLT receptors and is much less active on normal airways than LTC 4 or LTD 4 . However, early studies indicated that LTE 4 caused skin swelling in human subjects as potently as LTC 4 and LTD 4 , that airways of asthmatic subjects (particularly those that were aspirin sensitive) were selectively hyperresponsive to LTE 4 , and that a potential distinct LTE 4 receptor was present in guinea pig trachea. Recent studies have begun to uncover receptors selective for LTE 4 : P2Y 12 , an adenosine diphosphate receptor, and CysLT E R, which was observed functionally in the skin of mice lacking the type 1 and 2 cysLT receptors. These findings prompt a renewed focus on LTE 4 receptors as therapeutic targets that are not currently addressed by available receptor antagonists. (J Allergy Clin Immunol 2009;124:406-14.) 
Abbreviations used
cysLT: Cysteinyl leukotriene CysLT 1 R: Type 1 cysteinyl leukotriene receptor CysLT 2 R: Type 2 cysteinyl leukotriene receptor ERK: Extracellular signal-regulated kinase GPCR: G protein-coupled receptor LT: Leukotriene LTC 4 S: Leukotriene C 4 synthase MIP-1b: Macrophage inflammatory protein 1b PG: Prostaglandin PPAR-g: Peroxisome proliferator-activated receptor g SRS-A: Slow-reacting substance of anaphylaxis WT: Wild-type perspective, from its discovery to the identification of its receptors and mechanisms of action.
DISCOVERY OF LTE 4
The slow-reacting substance of anaphylaxis (SRS-A), so named by Brocklehurst, 1 was identified as a substance generated by in vitro antigen/allergen challenge of perfused lungs of actively sensitized guinea pigs or human lung fragments of allergic patients requiring resection. Its potent constrictor activity on guinea pig or human bronchioles in the presence of an antihistamine provided compelling evidence for its potential role in asthma. The initial analyses into the physical characteristics and composition of SRS-A from the rat suggested possible sulfur content. 2 This led to the identification by Murphy et al 3 of LTC 4 , the first component of SRS-A, by loading a mastocytoma cell line with [ 35 S]cysteine and identifying the radiolabeled component released in response to activation with calcium ionophore. LTC 4 was composed of a metabolite of arachidonic acid (eicosatetraenoic acid) with 3 conjugated double bonds and a peptide adduct through a sulfur bridge. The exact stereochemistry of the lipid and the amino acid sequence of the S-linked peptide of LTC 4 were obtained by comparing purified natural SRS-A with candidate synthetic cysLTs prepared by E. J. Corey. 4 These synthetic cysLTs showed bioactivity consistent with the functional definition of SRS-A offered by Brocklehurst, 1 who noted that a range of activities could contract the guinea pig ileum in the presence of an antihistamine.
Because we had anticipated that the activity of SRS-A could be attributed to a single product, we were surprised to find that partially purified SRS-A from the peritoneal cavity of rats GLOSSARY ARACHIDONIC ACID: Arachidonic acid is the precursor for both LTs and prostaglandins and is found on the nuclear membrane. Together, LTs and prostaglandins are called eicosanoids.
ASPIRIN-EXACERBATED RESPIRATORY DISEASE (AERD):
AERD consists of a clinical constellation of nasal polyposis with eosinophilic sinusitis, asthma, and idiosyncratic sensitivity to nonsteroidal antiinflammatory agents that inhibit COX-1. Treatment of patients with AERD includes LT inhibitors.
COX-2:
COX-2 is induced by LPS, IL-1, and IL-2 to produce prostaglandin intermediates from arachidonic acid.
CYSTEINYL LEUKOTRIENE (cysLT): LTs, so named because of their generation from ''leuko''cytes and conserved 3-double-bond ''trienes,'' are generated from arachidonic acid by 5-lipoxygenase/5-lipoxygenaseactivating protein. Conversion of LTA 4 to LTC 4 by means of addition of glutathione is the first step to generating cysLTs. LTA 4 hydrolase converts LTA 4 to LTB 4 . The major sources of LTC 4 S (and thus cysLTs) are eosinophils, basophils, and macrophages. Mast cells make both LTC 4 S and, along with neutrophils and macrophages, LTA 4 hydrolase.
CYSTEINYL LEUKOTRIENE RECEPTOR (CysLTR):
Both cysLT receptors and LTB 4 receptors are 7-transmembrane GPCRs. CysLT receptors can be upregulated by IL-4. LTB 4 uses 2 receptors, BLT1 and BLT2, which are expressed on most tissues and upregulated by IFN-g and promote neutrophil chemotaxis when activated by LTB 4 .
DYNAMIC COMPLIANCE: Airway compliance is a measure of volume change per unit of pressure. Lungs from patients with longstanding asthma have been reported to show decreased compliance, perhaps because of airway remodeling and associated fibrosis.
INDOMETHACIN:
Indomethacin inhibits COX-1 and can trigger AERD.
IL-6: IL-6 primes for T H 2 effector cells, inhibits the suppressive functions of CD4 1 CD25 1 regulatory T cells, and protects mast cells from apoptosis.
IL-10:
Generally associated with dampening immune responses, IL-10 decreases mast cell functions, such as IgE-mediated activation and anaphylaxis, in murine models.
IL-13: IL-13 and IL-6 can be produced by mast cells in response to activating signals, such as IL-33.
''LUKASTS'': Montelukast, pranlukast, and zafirlukast all block the CysLT 1 R, whereas biosynthetic pathway inhibitors, such as zileuton, block the production of both cysLTs and LTB 4 .
MACROPHAGE INFLAMMATORY PROTEIN 1b (MIP-1b):
MIP-1 is involved in the chemotaxis and activation of monocytes. CysLTs can induce MIP-1b and MIP-1a production from monocytes through the CysLT 1 R.
PERMEABILITY-ENHANCING ACTIVITY:
Activated vascular endothelium allows leakage of dyes (eg, Evans blue and fluorescein isothiocyanate-albumin) into the extravascular space, making tissues appear colored (blue) or fluorescent (fluorescein isothiocyanate).
PERTUSSIS TOXIN:
Pertussis toxin inhibits the function of GPCRs through adenosine diphosphate ribosylation of Ga.
PULMONARY RESISTANCE: Mechanical factors that limit alveolar access to air. Pulmonary resistance is calculated by using Ohm's and Poiseuille's laws, which factor in the pressure difference at the mouth and alveoli, the rate of airflow, viscosity, and the length and radius of the airways.
PROSTAGLANDIN D 2 (PGD 2 ):
A mast cell eicosanoid made in large quantities after IgE-mediated mast cell activation. PGD 2 levels are increased after allergen challenge, and it functions as a bronchconstrictor and vasodilator and is associated with eosinophil influx.
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR g (PPAR-g):
Transcription factors in the nuclear hormone receptor superfamily that binds retinoic acid. PPAR-g1 and PPAR-g2 are expressed in adipocytes and decrease proinflammatory cytokine production from macrophages, B and T cells, eosinophils, dendritic cells, and airway epithelium.
RESPIRATORY BURST:
The neutrophil oxidative burst generates superoxide anions and reactive oxygen intermediates important for microbial killing through the reduced nicotinamide adenine dinucleotide phosphate oxidase complex. Mutations in this complex (gp91, gp67 phox , gp22, and gp47 phox ) cause chronic granulomatous disease and recurrent infections with organisms such as Staphylococcus aureus, Aspergillus species, Serratia species, and Burkholderia cepacia.
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J ALLERGY CLIN IMMUNOL VOLUME 124, NUMBER 3 undergoing IgGa-dependent anaphylaxis was comprised of 3 products, all with 3 conjugated double bonds and each having contractile activity for the guinea pig ileum. By comparison with active and inactive standards with different peptide adducts, we recognized the 3 components of authentic SRS-A to elute with the retention times of the previously defined LTC 4 4,5 and 2 additional theoretic structures, LTD 4 and LTE 4 .
6 These 2 additional structures differed from LTC 4 in that the former possessed the sulfurlinked glutathione tripeptide adduct composed of glutamic acid, glycine, and cysteine, whereas LTD 4 lacked the glutamic acid residue and LTE 4 lacked both the glutamic acid and glycine residues (Fig 1) . Because LTC 4 is the only intracellular cysLT generated by LTC 4 synthase (LTC 4 S), 7 it seemed likely that LTD 4 was formed extracellularly from LTC 4 by means of deletion of glutamic acid (by a g-glutamyl transpeptidase or g-glutamyl leukotrienase) after the export of the former compound to the extracellular space. Further removal of glycine from the remaining dipeptide adduct of LTD 4 by dipeptidases accounted for LTE 4 with a remaining cysteine adduct. 6, 8 That LTC 4 underwent enzymatic modification in the extracellular space accounted for the fact that it was the only component of SRS-A to be detected in single-cell systems, whereas all 3 components were detected in biologic fluids. These early studies not only showed natural SRS-A to be composed of 3 cysLTs but also demonstrated that each cysLT had contractile activity for ileal smooth muscle in vivo (Fig 2) and permeability-enhancing activity by means of intradermal injection into the guinea pig prepared with Evans blue dye. 6 Members of the pharmaceutical industry then used contractile assays to characterize the putative ''receptors'' for cysLTs and to identify potential antagonists. This approach permitted the development of the prototypes of the orally available CysLT 1 R-selective antagonists (''lukasts'') more than a decade before any receptor was defined in molecular terms. Human CysLT 1 R and CysLT 2 R were cloned by Evans and colleagues. 9, 10 CysLT 1 R exhibited a marked preference for binding of LTD 4 over LTC 4 and was the only receptor that was competitively blocked by the lukasts. CysLT 2 R had equal affinity for LTD 4 and LTC 4 and bound LTD 4 at 10-fold lower affinity than did CysLT 1 R. It was surprising that LTE 4 did not register as an appreciable binding ligand for these ''classical'' receptors expressed individually in cloned cells. The poor affinity of LTE 4 for these cloned receptors prompted some to suggest that LTE 4 was a relatively impotent extracellular metabolite and perhaps discouraged others from seeking a third receptor. In contrast, we believed that the LTE 4 agonist activity that had been demonstrated in pharmacologic studies in guinea pigs and human subjects was impressive and that the greater stability of LTE 4 relative to the other cysLTs might favor a distinct pathobiologic role. The sections that follow will consider some of the early findings for LTE 4 , favoring the existence of a distinct receptor and revealing its relative biologic stability. We will also consider the noteworthy potency of LTE 4 as a contractile agonist in guinea pig airways and in the human microvasculature, as well as a proinflammatory function based on studies using aerosolization challenge in human subjects with asthma and in allergen-sensitized mice. These studies have been key to the recognition of 2 functional receptors activated by LTE 4 by 2 different laboratories with different experimental approaches.
EARLY PHARMACOLOGY OF LTE 4 IN ANIMALS
The potency of LTE 4 for contraction of guinea pig tracheal spirals in vitro was 10-fold greater than that of either LTC 4 or LTD 4 , whereas for guinea pig parenchymal strips, the potency of LTD 4 was 6-fold that of LTE 4 and 20-fold that of LTC 4 . Furthermore, the concentration effect for LTD 4 and LTE 4 on parenchymal strips observed by Drazen et al 12 was biphasic, with the initial low concentration effect (studied only for LTD 4 ) being competitively antagonized by FPL55712. In contrast, LTC 4 was the least potent ligand and produced only a linear response. 11, 12 When these ligands were administered intravenously to the intact anesthetized or unanesthetized guinea pig, LTD 4 and LTC 4 elicited a small increase in pulmonary resistance compared with the magnitude of the decrease in dynamic compliance, whereas LTE 4 decreased compliance together with a robust increase in resistance, indicating both peripheral and central airway effects. 12, 13 Another distinctive effect of LTE 4 was that it enhanced the contractile responses of the guinea pig tracheal smooth muscle to histamine, a property not shared with LTC 4 or LTD 4 . The latter effect of LTE 4 could be prevented by treatment of the tracheal tissue with indomethacin, indicating a key role for a COX product. 14 Together, these in vitro and in vivo functional findings suggested the presence of 3 receptors for cysLTs: a high-affinity receptor for LTD 4 , a lower-affinity receptor for LTC 4 , and a separate receptor for LTE 4 , with the latter potentially capable of eliciting the secondary production of a prostanoid (Table I) . 12 The observed ratio of potency for the 3 cysLTs in different tissues could reflect not only the profile of receptor expression in the target tissue but also the rate of conversion of 1 cysLT to another of greater or lesser activity. This is readily demonstrated when LTC 4 and LTD 4 are separately applied to the guinea pig ileum at concentrations sufficient to result in their maximum isotonic responses. Tritiated LTC 4 has a 60-second latent period before initiating a linear contractile response to 80% of maximum over 2 minutes, which is followed by a further contraction associated with slow metabolism to the more potent tritiated LTD 4 . There is negligible conversion of tritiated LTC 4 to tritiated LTD 4 / LTE 4 during the linear phase. Furthermore, the inclusion of serine borate to block bioconversion of LTC 4 to LTD 4 by membrane g-glutamyl transpeptidase does not change the response of the tissue to LTC 4 , thus confirming that this response is mediated by a specific LTC 4 receptor. 15 In contrast, tritiated LTD 4 initiated an immediate linear contraction that reached maximum at 1 minute and then decreased sharply with linear conversion to tritiated LTE 4 , which has only one quarter the potency of LTD 4 in this assay. When the mucosa containing the dipeptidase activity had been removed from the ileal muscle, the linear contractile response to tritiated LTD 4 was maintained, reflecting the loss of metabolism to tritiated LTE 4 by means of removal of the glycine. These findings nicely reflect the exquisite receptor specificity of the cysLT system that is conferred by modifications of the peptide adduct (Fig 3) .
EARLY STUDIES OF LTE 4 METABOLISM
The products of the granulocyte respiratory burst, which are abundant with inflammation, can alter the stability of each cysLT in vitro and in vivo. Phorbol 12-myristate 13-acetate-activated human neutrophils converted each cysLT to their subclass-specific S-diastereoisomeric sulfoxides, which retained their ability to be detected by cysLT-specific antibodies but lost greater than 95% of function. Each sulfoxide was further processed to identical diastereoisomers of 6-trans LTB 4 , which were nonfunctional and no longer immunoreactive with the original antibodies. This neutrophil-mediated inactivation involved interaction of released myeloperoxidase, newly generated H 2 O 2 , and extracellular chloride ion to form hypochlorous acid. Dose-dependent attack on the sulfur bridge during hypochlorous acid formation showed that LTE 4 was substantially more resistant than the other cysLTs. 16, 17 Systemic metabolism of the cysLTs begins after export of intracellular LTC 4 and its rapid extracellular physiologic sequential conversion through LTD 4 to LTE 4 . Studies using intravascular administration of labeled LTE 4 or LTC 4 to human subjects indicate that approximately 5% is recovered in the urine and is composed of LTE 4 and N-acetyl LTE 4 . At the level of tissue peroxisomes, omega oxidation at the C-terminus yields 20-COOH-LTE 4 and formation of the 20-CoA ester, which allows for sequential b oxidation with shortening of the carbon chain to 18-COOH-dinor-LTE 4 and beyond. [18] [19] [20] EARLY PHARMACOLOGY OF LTE 4 
IN HUMAN SUBJECTS
Although the early pharmacology of the 3 sequentially generated cysLTs identified LTE 4 as the most stable in physiologic and pathobiologic models, clinical attention shifted to LTD 4 and LTC 4 , which on inhalation were up to 1000 times as potent as histamine.
21,22 LTE 4 was only 39 times as potent as histamine in reducing maximum expiratory flow at 30% of vital capacity Reproduced from Drazen et al 12 with kind permission of Springer Science and Business Media. C dyn , Dynamic compliance; R L , lung resistance. *In vitro activity is recorded as the ratio of the molar concentration of LTs required to achieve a half-maximal response to the concentration of histamine required to achieve an equivalent response. In vivo activity is recorded as the response to infusion of 3 mg/kg LT (11, minimal response; 41, maximal response).
J ALLERGY CLIN IMMUNOL VOLUME 124, NUMBER 3 in healthy human subjects. [21] [22] [23] Although each cysLT was a potent bronchoconstrictor in patients with bronchial asthma, there was little difference between asthmatic and healthy control subjects in sensitivity to cysLTs, which is in contrast to the hyperresponsiveness to histamine or methacholine that is characteristic of asthma. 24 An exception to that rule is in aspirin-exacerbated respiratory disease, an asthma variant associated with marked overproduction of the cysLTs. In these subjects Christie et al 25 showed selective hyperresponsiveness to LTE 4 , but not to LTC 4 , relative to that seen in aspirin-tolerant asthmatic subjects.
Because we had recognized that LTE 4 induced permeability in guinea pig skin over the same dose range (5.0-50 ng) as for LTC 4 and LTD 4 , 6 we compared their action at 1.0 nmol per site by means of intradermal injection in 3 human volunteers. Each cysLT elicited a wheal-and-flare response by 10 minutes, which peaked at 1 to 2 hours with a 10-to 20-mm wheal and a 20-to 25-mm flare. The wheal resolved by 4 hours (Fig 4) , whereas the flare was still evident at 6 hours. 26 The 3 cysLTs produced equiactive responses in each subject. Biopsy specimens at 2 hours showed dermal edema, marked and uniform dilation of the microvasculature, and deep venules with activation of endothelial cells and some dilation of arterioles. That LTE 4 was apparently as potent a permeability factor as LTC 4 and LTD 4 in 2 species clearly indicated that it was not a disposal product. The advent of molecular biology and the development of gene-deleted mice later permitted the use of murine microvasculature to seek a functional receptor for LTE 4 .
FUNCTIONAL AND PHARMACOLOGIC CHARACTERIZATION OF CysLT E R, A CUTANEOUS RECEPTOR PREFERENTIAL FOR LTE 4
In addition to addressing the pharmacology of the cysLTs during the 1980s, we began to characterize LTC 4 S, the integral protein of the outer nuclear membrane responsible for biosynthesis of LTC 4 , by means of conjugation of glutathione to LTA 4 . 7 After expression cloning of human LTC 4 S and then homology cloning of murine LTC 4 S, 27, 28 we turned to targeted disruption of murine LTC 4 S to explore for phenotypic characteristics that might depend on the functions of the cysLTs. 29 In a model of passive cutaneous anaphylaxis, there was more than 50% reduction in ear swelling (indicative of vascular leak) in LTC 4 S-deficient mice (Ltc4s on the prior cloning of these 7-transmembrane, human G protein-coupled receptors (GPCRs). 9, 10 In response to an intraperitoneal injection of zymosan, a yeast cell-wall material that elicits cysLT generation from macrophages, both the Ltc4s 2/2 and Cyslt1r
2/2
, but not the Cyslt2r
, strains showed approximately 50% reductions in vascular leak, implying a key role for cysLTs acting at CysLT 1 R for this innate immune response.
The responsiveness of the murine vasculature to the cysLTs suggested that the existence of a distinct LTE 4 -reactive receptor could be proved by studying cysLT-dependent swelling responses in mice deficient in both receptors. This strain (Cyslt1r/Cyslt2r 2/2 ) was created by intercrossing the Cyslt1r 2/2 and Cyslt2r
strains. 32 The resulting double-receptor deficiency of the Cyslt1r/ Cyslt2r 2/2 strain was confirmed by the absence of both receptor transcripts. We then examined the dose-dependent ear edema elicited by each cysLT in the respective Cyslt1r
2/2 , and Cyslt1r/Cyslt2r 2/2 strains. 32 The dose-dependent ear edema elicited by means of injection of LTD 4 and LTC 4 in the Cyslt1r/Cyslt2r 2/2 strain was equivalent to that in the WT control animals, indicating the presence of a previously unrecognized receptor. The Cyslt1r/Cyslt2r 2/2 mice were especially sensitive to LTE 4 , exhibiting the same extent of ear swelling in response to an LTE 4 dose of 0.008 nmol as the response of the WT mice to 0.5 nmol (a 64-fold increase in sensitivity to LTE 4 ). Histologic analysis of biopsy specimens at 30 and 240 minutes showed an exaggerated magnitude and duration of ear edema without cellular infiltration in response to LTE 4 in the Cyslt1r/Cyslt2r 2/2 strain. The LTE 4 -mediated vascular leak in the Cyslt1r/Cyslt2r 2/2 strain was markedly inhibited by pretreatment of the mice with pertussis toxin or a Rho kinase inhibitor, supporting that the mechanism involved a GPCR linked to Gai proteins and Rho kinase. 32 Additionally, the response to LTE 4 was blocked by approximately 30% by means of treatment of the mice with indomethacin, which is reminiscent of the indomethacin sensitivity of the LTE 4 response of guinea pig tracheal rings. 14 The particular sensitivity of this novel receptor to LTE 4 prompts the designation of CysLT E R rather than a number until it is cloned (Fig 5) .
The discovery of a CysLT E R prompted us to re-evaluate the findings in WT mice and single-receptor-deficient strains. The permeability response to 0.5 nmol LTC 4 or LTD 4 was 50% reduced in Cyslt1r 2/2 mice and normal in magnitude but delayed in Cyslt2r 2/2 mice, suggesting that CysLT 1 R is the major signaling receptor for LTC 4 and LTD 4 , whereas CysLT 2 R is a negative regulator of CysLT 1 R. LTE 4 -elicited vascular leak was not attenuated in the Cyslt1r 2/2 mice but delayed and sustained in the Cyslt2r 2/2 strain, suggesting that CysLT E R is the dominant receptor for this ligand and that CysLT 2 R is again a negative regulator. That the enhanced sensitivity to LTE 4 -induced ear edema observed in the Cyslt1r/Cyslt2r 2/2 strain was not seen with either single-receptor-null strain, Cyslt1r 2/2 or Cyslt2r 2/2 , implies that both CysLT 2 R and CysLT 1 R negatively regulate CysLT E R. Indeed, administration of the selective CysLT 1 R antagonist MK571 to Cyslt2r 2/2 mice mimicked the phenotype of the Cyslt1r/Cyslt2r 2/2 strain in terms of the markedly increased vascular leak of the ear to intradermal LTE 4 . This, of course, meant that MK571 was not an inhibitor of CysLT E R. Curiously, pretreatment with MK571 had opposing effects in WT mice and the Cyslt1r/Cyslt2r 2/2 strain. 32 Specifically, MK571 suppressed swelling of the skin in WT mice challenged intradermally with 0.5 nmol of LTD 4 , LTC 4 , or LTE 4 . In contrast, the same MK571 pretreatment and dose of ligand produced an enhanced response to cysLTs in Cyslt1r/Cyslt2r 2/2 mice. Thus MK571, which is a prototype of the lukast drugs, potentiates responses apparently mediated through CysLT E R, in a setting in which neither CysLT 1 R nor CysLT 2 R is present to impart negative regulation. It is possible that MK571, which is now known to block certain transporter proteins and some purinergic (P2Y) receptors for nucleotides, 33, 34 might block a yet-to-be-defined receptor with negative regulatory properties for CysLT E R. 
DISCOVERY THAT THE P2Y 12 RECEPTOR MEDIATES MAST CELL ACTIVATION AND PULMONARY INFLAMMATION BY LTE 4
As is the case for many effector cells of bone marrow origin, mast cells express both CysLT 1 R and CysLT 2 R.
35,36 LTC 4 and LTD 4 both induce calcium flux, cytokine and chemokine generation, phosphorylation of extracellular signal-regulated kinase (ERK), and proliferation of human mast cells in vitro. [35] [36] [37] These responses, like those of the cutaneous microvasculature, are regulated positively by CysLT 1 R but negatively regulated by CysLT 2 R based on experiments in which each receptor is selectively knocked down by using RNA interference in primary human mast cells. 38 During these studies, Jiang et al 38 made the unanticipated finding that LTE 4 exceeded the potency of LTC 4 and LTD 4 for increasing the numbers of human mast cells arising from cultures of cord blood-derived progenitor cells maintained in the presence of stem cell factor, IL-6, and IL-10.
37 Subsequently, Paruchuri et al 39 demonstrated that LTE 4 not only exceeded the potency of LTC 4 and LTD 4 as a mitogen for a human mast cell line, LAD2, but far exceeded its potency for causing the production of the inflammatory chemokine macrophage inflammatory protein-1b (MIP-1b) and was also substantially more potent for causing the expression of inducible COX-2 and promoting delayed prostaglandin D 2 (PGD 2 ) generation. Curiously, the latter effects required the activation of peroxisome proliferator-activated receptor g (PPAR-g), a nuclear transcription factor that is activated by several dietary lipids and eicosanoids. However, the effect of LTE 4 on PPAR-g is indirect because LTE 4 failed to activate a PPAR-g-driven reporter in bovine endothelial cells. 39 Indeed, the effects of LTE 4 on PGD 2 generation and MIP-1b production were sensitive to MK571 and pertussis toxin, whereas LTE 4 -mediated ERK activation was insensitive to MK571, and all LTE 4 responses were completely resistant to knockdowns of CysLT 1 R and CysLT 2 R. It was thus clear that mast cells expressed at least 1 previously unrecognized LTE 4 receptor that was MK571 resistant (and perhaps another that was sensitive).
Based on sequence homology between CysLT 1 R, CysLT 2 R, and the P2Y receptor family, it seemed likely that a putative CysLT 3 R might be among the orphan P2Y-like GPCRs or even a known member. Human mast cells express several such receptors, 40 including the P2Y 12 receptor, a Gai-linked receptor for adenosine diphosphate and the target of thienopyridine antithrombotic drugs. Because a computer modeling study had predicted that LTE 4 might be a surrogate ligand for this receptor, 41 we sought to determine whether recombinant P2Y 12 receptors reacted to LTE 4 and mediated the LTE 4 -dependent signaling events recognized in mast cells. LTE 4 induced the activation of ERK in Chinese hamster ovary cells stably transfected with human P2Y 12 receptors exceeding the potency of LTD 4 . This signaling event was sensitive to pertussis toxin but resistant to MK571 (unpublished data). Although P2Y 12 did not bind LTE 4 directly, knockdown of P2Y 12 receptors by RNA interference blocked LTE 4 -mediated MIP-1b generation and PGD 2 production by LAD2 cells without significantly altering their responses to LTD 4 . Because LTE 4 (but not LTD 4 ) was previously shown to induce bronchial eosinophilia when administered by means of inhalation to asthmatic human subjects, 42 we sought to determine whether pulmonary inflammation amplified by LTE 4 in mice depended on P2Y 12 receptors. Administration of LTE 4 , but not LTD 4 , to the airways of sensitized BALB/c mice potentiated eosinophilia, goblet cell metaplasia, and expression of IL-13 in response to low-dose aerosolized ovalbumin. These effects were completely intact in the Cyslt1r/Cyslt2r 2/2 mice but were completely blocked by oral administration of the P2Y 12 receptor-selective antagonist clopidogrel. The effect of P2Y 12 receptor blockade was similar to the effect of platelet depletion with an antibody, suggesting that LTE 4 acted as an agonist for platelet activation in the pulmonary vasculature in this model. Importantly, clopidogrel had failed to block the response of the murine skin microvasculature to LTE 4 , indicating that P2Y 12 receptors are separate and distinct from the CysLT E R in the skin. 32 
EPILOGUE
At this early stage, clinical considerations must be circumspect and limited based on these findings for receptors in naive mice in model systems or with targeted disruption of classical receptors. Nonetheless, the history of cysLT-mediated permeability effects in guinea pigs and human subjects suggests that this important aspect of the inflammatory process is as responsive to LTE 4 as to its precursors, LTC 4 and LTD 4 , which are only transiently present during an inflammatory process. The finding that the classical CysLT 1 R and CysLT 2 R are negative regulators of CysLT E R function in mice was certainly unexpected but is supported by literature showing CysLT 2 R to be a negative regulator of CysLT 1 R for murine and human mast cell proliferation 38 and by the potentiation of LTE 4 -mediated skin swelling of Cyslt2r 2/2 mice occurring in the presence of a CysLT 1 R antagonist. 32 In an inflammatory process it seems possible that the generation of LTC 4 /LTD 4 and occupancy of classical receptors followed by receptor internalization 43 could allow increased CysLT E R function. The identification of at least 2 LTE 4 -reactive GPCRs provides potential mechanistic explanations for the potency of LTE 4 as an inducer of vascular permeability and potentiator of mucosal inflammation, which were identified by previous pharmacologic profiling studies in human and guinea pig tissues. [13] [14] [15] 25, 26, 42 Moreover, the fact that P2Y 12 (and not CysLT E R) is responsible for LTE 4 -mediated activation and proliferation of mast cells, as well as amplification of allergic pulmonary inflammation, indicates that the receptors for LTE 4 evolved to serve functions that are anatomically and contextually distinct yet potentially complementary in inflammation (Fig 6) .
